Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-ALIVE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 24 Oct 2018 Results of an integrated analysis (n=1248) assessing the safety events across indications in patients who received IV golimumab in three phase III studies (GO-FURTHER, GO-VIBRANT and GO-ALIVE), presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 16 Jun 2018 Results of a safety integrated analysis of Golimumab treatment from phase 3 studies (GO-FURTHER, GO-VIBRANT and GO-ALIVE; n=1279) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 01 Feb 2018 Results published in The Journal of Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top